Drs. Gilberto Lopes and Chinmay Jani (IMAGE)
Caption
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, its cost raises questions about sustainability, prevention and access. The findings, published in JCO Global Oncology, are accompanied by an editorial, titled “Durvalumab in Limited-Stage Small Cell Lung Cancer: Clinical Triumph and Toward Sustainable Value.”
Credit
Sylvester Comprehensive Cancer Center
Usage Restrictions
Use with attribution
License
Original content